Drug Profile
CPK 850
Alternative Names: CPK850; CPK850 Gene Therapy; scAAV8-pRLBP1(short)-hRLBP1 vector; scAAV8-RLBP1Latest Information Update: 06 Jan 2023
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Retinitis pigmentosa
Most Recent Events
- 06 Jan 2023 Phase II trial in Retinitis pigmentosa is still ongoing in Sweden (NCT03374657)
- 24 Jul 2020 Phase II trial in Retinitis pigmentosa is still ongoing in Sweden (NCT03374657)
- 22 Jul 2020 Novartis plans to submit first regulatory application for Retinitis pigmentosa in or after 2026 (Novartis pipeline, February 2022)